Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Use of AI in Cancer Screenings

Medical imaging, an integral part of the cancer screening process, continues to experience rapid, year-over-year growth. Unfortunately, available radiologists cannot keep pace with the demand for their services fueled by the continued growth in cancer screening. New solutions are in desperate need to support diagnosis and improve workflows. Can AI play an important role in…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Medical imaging, an integral part of the cancer screening process, continues to experience rapid, year-over-year growth. Unfortunately, available radiologists cannot keep pace with the demand for their services fueled by the continued growth in cancer screening. New solutions are in desperate need to support diagnosis and improve workflows. Can AI play an important role in cancer screenings today and in the future? That’s what Health and Life Sciences at the Edge’s Tyler Kern wants to find out, and Intel’s Business Development and Sales Lead, Ryan Kim, and Lunit’s Director of INSIGHT Marketing, Jonathan Yang, have answers. 

The disparity between the growing need for cancer screenings and the radiologists available to do the work can lead to missed early detection of cancers on chest X-rays and mammograms. Yang says this situation can create a big problem. “Regarding mammography, a high number of screenings can be read as false-positive, meaning that only a single digit percent of those recalled are retested,” he explains. “So, this is where AI can come in. AI isn’t here to replace radiologists, but it is here to support them, especially regarding cancer screening.” Yang sees many potential benefits AI can provide in assisting cancer screenings for patients, physicians, and medical institutions.

AI-driven solutions can reduce physicians’ reading time. Yang states, “This allows physicians to spend more time on the hard and tough cases. It also enables early detection of disease.”

Integrating AI into the cancer screening process is a seamless process today. Yang says there are two ways to integrate AI into the diagnostic imaging workflow. The first is when an image is acquired, and the second is during the image interpretation process. In both cases, Luni partners with companies with imaging platforms to make the integration seamless for healthcare institutions.

The utilization of Intel’s OpenVINO™ Toolkit assists in processing images quickly and minimizing the time from X-ray imaging to diagnosis. With OpenVINO technology, diagnostics can run on a CPU-only mode of operations, which reduces the cost of operations while delivering on the imaging speed physicians need. 

Learn more about AI-enabled cancer screening solutions by connecting with Ryan Kim and Jonathan Yang on LinkedIn or visit Intel Health and Life Sciences and Lunit’s websites. 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512